RS50722B - 2-okso-1,2,4,5-tetrahidro-1,3-benzdiazepin-3-il-piperidini korišćeni u vidu cgrp antagonista - Google Patents

2-okso-1,2,4,5-tetrahidro-1,3-benzdiazepin-3-il-piperidini korišćeni u vidu cgrp antagonista

Info

Publication number
RS50722B
RS50722B RSP-2009/0019A RSP20090019A RS50722B RS 50722 B RS50722 B RS 50722B RS P20090019 A RSP20090019 A RS P20090019A RS 50722 B RS50722 B RS 50722B
Authority
RS
Serbia
Prior art keywords
benzdiazepin
tetrahydro
oxo
cgrp antagonists
boehringer ingelheim
Prior art date
Application number
RSP-2009/0019A
Other languages
English (en)
Inventor
Stephan Georg Mueller
Klaus Rudolf
Philipp LUSSTENBERGER
Dirk Stenkamp
Marco Santagostino
Fabio Paleari
Alexander Dreyer
Kirsten Arndt
Henri Doods
Gerhard Chaenzle
Original Assignee
Boehringer Ingelheim International Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2005/003094 external-priority patent/WO2005092880A1/de
Application filed by Boehringer Ingelheim International Gmbh. filed Critical Boehringer Ingelheim International Gmbh.
Publication of RS50722B publication Critical patent/RS50722B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)

Abstract

CGRP antagonisti opšte formule I koji su izabrani iz grupe koja sadrži: njihovi enantiomeri, njihovi dijastereomeri, njihovi hidrati, njihove smeše i njihove soli, kao i hidrati soli, a posebno njihove fiziološki prihvatljive soli sa neorganskim ili organskim kiselinama ili bazama. Prijava sadrži još 17 patentnih zahteva.
RSP-2009/0019A 2005-03-23 2006-03-21 2-okso-1,2,4,5-tetrahidro-1,3-benzdiazepin-3-il-piperidini korišćeni u vidu cgrp antagonista RS50722B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2005/003094 WO2005092880A1 (de) 2004-03-29 2005-03-23 Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
PCT/EP2006/002557 WO2006100026A1 (de) 2005-03-23 2006-03-21 2-oxo-1,2,4,5-tetrahydro-1,3-benzdiazepin-3-yl-piperidine als cgrp-antagonisten

Publications (1)

Publication Number Publication Date
RS50722B true RS50722B (sr) 2010-08-31

Family

ID=36406232

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0019A RS50722B (sr) 2005-03-23 2006-03-21 2-okso-1,2,4,5-tetrahidro-1,3-benzdiazepin-3-il-piperidini korišćeni u vidu cgrp antagonista

Country Status (19)

Country Link
EP (2) EP1863791B1 (sr)
JP (1) JP4210322B2 (sr)
KR (1) KR20070113317A (sr)
CN (2) CN101146799A (sr)
AU (1) AU2006226544A1 (sr)
CA (1) CA2600189A1 (sr)
DE (1) DE502006002066D1 (sr)
DK (1) DK1863791T5 (sr)
EA (1) EA012590B1 (sr)
ES (1) ES2317512T3 (sr)
HR (1) HRP20090011T3 (sr)
MY (1) MY144635A (sr)
NO (1) NO20073758L (sr)
PL (1) PL1863791T3 (sr)
PT (1) PT1863791E (sr)
RS (1) RS50722B (sr)
SI (1) SI1863791T1 (sr)
WO (1) WO2006100026A1 (sr)
ZA (1) ZA200705852B (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en) 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
EP1770086A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
MX2008015562A (es) * 2006-06-08 2008-12-17 Boehringer Ingelheim Int Tratamiento de trastornos gastrointestinales con antagonistas de cgrp.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2005003094A1 (en) 2003-07-03 2005-01-13 Poseidon Pharmaceuticals A/S Diarylmethyl derivatives as potassium channel modulators
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
EP1619187A1 (de) 2004-07-23 2006-01-25 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung von 3-(4-Piperidinyl)- 2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-on

Also Published As

Publication number Publication date
PT1863791E (pt) 2008-12-15
EA012590B1 (ru) 2009-10-30
PL1863791T3 (pl) 2009-04-30
EP1992349A1 (de) 2008-11-19
WO2006100026A8 (de) 2007-02-08
WO2006100026A1 (de) 2006-09-28
DE502006002066D1 (de) 2008-12-24
EA200701843A1 (ru) 2008-02-28
CN101146799A (zh) 2008-03-19
KR20070113317A (ko) 2007-11-28
EP1863791B1 (de) 2008-11-12
MY144635A (en) 2011-10-14
ES2317512T3 (es) 2009-04-16
JP4210322B2 (ja) 2009-01-14
HRP20090011T3 (en) 2009-02-28
JP2008533083A (ja) 2008-08-21
CN101146790A (zh) 2008-03-19
DK1863791T3 (da) 2009-02-16
EP1992349B1 (de) 2013-07-31
CA2600189A1 (en) 2006-09-28
ZA200705852B (en) 2009-12-30
EP1992349B8 (de) 2013-10-09
SI1863791T1 (sl) 2009-04-30
EP1863791A1 (de) 2007-12-12
AU2006226544A1 (en) 2006-09-28
DK1863791T5 (da) 2010-10-04
NO20073758L (no) 2007-10-19

Similar Documents

Publication Publication Date Title
RS51516B (sr) Dodatna heterociklična jedinjenja i njihovo korišćenje kao antagonista metabotropnih receptora glutamata
MEP51408A (en) Selected cgrp antagonists, method for production and use thereof as medicament
RS20050311A (en) Selected cgrp antagonists,method for production and use thereof as medicament
CY1108744T1 (el) 2-οξο-1,2,4,5-τετραϋδρo-1,3-βενζοδιαζεπιν-3-υλ-πιπεριδινες ως ανταγωνιστες της cgrp
EA200601459A1 (ru) НОВЫЕ АМИДЫ КАРБОНОВЫХ КИСЛОТ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
WO2009065919A3 (de) Organische verbindungen
HRP20080027T3 (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
WO2009065920A3 (de) Verbindungen
RS52534B (sr) Makrociklična jedinjenja hinoksalina kao inhibitori hcv ns3 proteaze
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
RS52189B (sr) Inhibitori 5-lipoksigenaza-aktivirajućeg proteina (flap)
MA28685B1 (fr) Derives de la quinazolinone, antagonistes de la vanilloide
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
SG169337A1 (en) Aryl sulfonamides with an analgesic action
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
CY1105734T1 (el) Nεα προ-φαρμακα του 1-μεθυλο-2-(4-αμιδινοφαινυλαμινομεθυλο)-βενζιμιδαζολ-5-υλιο-καρβοξυλικο οξυ-(ν-2-πυριδυλο-ν-2-υδροξυκαρβονυλαιθυλο)-αμιδιου, η παρασκευη και η χρησιμοποιηση τους ως φαρμακων
EA201000612A1 (ru) Антагонисты cgrp-пептиды
RS53428B (sr) Kompozicije i antivirusna aktivnost supstituisanih azaindoloksosirćetnih piperazin derivata
AR074204A1 (es) Arilpiperazinas y su uso como antagonistas alfa -2c
EA200970192A1 (ru) Производные 5,6-бисарил-2-пиридин-карбоксамида, их получение и их применение в терапии в качестве антагонистов рецепторов уротензина ii
RS50722B (sr) 2-okso-1,2,4,5-tetrahidro-1,3-benzdiazepin-3-il-piperidini korišćeni u vidu cgrp antagonista
RS53622B1 (sr) Disupstituisana jedinjenja tetrahidrofuranila kao antagonisti receptora bradikinina-b1
NO20043115L (no) Substituerte diketopiperaziner som oksytocin antagonister
WO2009034029A3 (de) 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
HRP20090190T1 (en) Pharmaceutical composition comprising a salt of mirtazapine